Microbiome's Universe: Impact on health, disease and cancer treatment DOI
Zsuzsánna Réthi‐Nagy,

Szilvia Juhász

Journal of Biotechnology, Journal Year: 2024, Volume and Issue: 392, P. 161 - 179

Published: July 14, 2024

Language: Английский

Exosomes as targeted diagnostic biomarkers: Recent studies and trends DOI

Aida Abbasi Marjani,

Nader D. Nader, Ayuob Aghanejad

et al.

Life Sciences, Journal Year: 2024, Volume and Issue: 354, P. 122985 - 122985

Published: Aug. 14, 2024

Language: Английский

Citations

10

Implications of nanotherapeutic advancements to leverage multi-drug resistant breast cancer: The state-of-the-art review DOI Creative Commons

Adhithya Aravindan,

Ashutosh Gupta, Sudheer Moorkoth

et al.

Journal of Drug Delivery Science and Technology, Journal Year: 2024, Volume and Issue: 100, P. 106007 - 106007

Published: Aug. 5, 2024

Globally, cancer is regarded as a severe health issue. Among these breast (BC), the second most common kind in women after skin cancer. According to statistical data from NIH Cancer Institute, expected number of cases was around 3 lakh people, with 7.1 % fatality rate. The rise multidrug resistance (MDR) British Columbia issue it lowers effectiveness existing treatments. Traditional MDR treatment approaches BC have drawbacks, including toxicity, high cost, early discharge, restricted drug load before target, and poor effectiveness. Preventing has depended heavily on developing innovative therapy delivery methods utilizing nanomedicine new diagnosing treating BC. This review discusses its pathophysiology relation tumor kinetics. It focuses latest therapeutic over traditional like Surgery, Chemotherapy, Nanomedicine, Phototherapy, Immunotherapy, Gene therapy. also describes diagnostic techniques using MRI/PET, Mammography, Microwave Sensing, In-silico methods, Molecular techniques, AI-machine learning-based tools. discussed limitations nanoparticles article aims identify efficient ways diagnose treat prevent recurrence.

Language: Английский

Citations

9

Biomolecule-based engineered nanoparticles for Cancer Theranostics DOI

Narayanan Parthasarathy,

Ramar Thangam, Babu Rithisa

et al.

Coordination Chemistry Reviews, Journal Year: 2025, Volume and Issue: 530, P. 216489 - 216489

Published: Feb. 3, 2025

Language: Английский

Citations

1

Ferroptosis crosstalk in anti-tumor immunotherapy: molecular mechanisms, tumor microenvironment, application prospects DOI
Y. F. Lu,

Xiao‐Ting Xie,

Lianxiang Luo

et al.

APOPTOSIS, Journal Year: 2024, Volume and Issue: 29(11-12), P. 1914 - 1943

Published: July 15, 2024

Language: Английский

Citations

7

Aromatase Inhibitors and Plasma Lipid Changes in Postmenopausal Women with Breast Cancer: A Systematic Review and Meta-Analysis DOI Open Access
Bálint Bérczi, Nelli Farkas, Péter Hegyi

et al.

Journal of Clinical Medicine, Journal Year: 2024, Volume and Issue: 13(6), P. 1818 - 1818

Published: March 21, 2024

Background: Women are typically diagnosed with estrogen receptor-positive breast cancer around the postmenopausal period when declining levels initiate changes in lipid profiles. Aromatase inhibitors (AI) used to prevent progression of cancer; however, a further reduction may have detrimental effects on levels, which was our working hypothesis. Methods: Our meta-analysis conducted profiles patients at baseline and different treatment time points. Results: We identified 15 studies, including 1708 patients. Studies using anastrozole (ANA), exemestane (EXE), letrozole (LET), tamoxifen (TMX) were involved. Subgroup analyses revealed that 3- 12-month administrations LET EXE lead negative tend alter profile undesirably, unlike ANA TMX. Conclusions: results suggest that, despite statistically significant results, not be sufficient cause severe dyslipidemia without cardiovascular comorbidities according AHA/ACC Guideline Management Blood Cholesterol. However, raise question monitoring AIs patients, especially those pre-existing risk factors such as dyslipidemia.

Language: Английский

Citations

6

A pH-responsive nanoplatform with dual-modality imaging for enhanced cancer phototherapy and diagnosis of lung metastasis DOI Creative Commons
Mujie Yuan, Zeyu Han, Yan Li

et al.

Journal of Nanobiotechnology, Journal Year: 2024, Volume and Issue: 22(1)

Published: April 15, 2024

Abstract To address the limitations of traditional photothermal therapy (PTT)/ photodynamic (PDT) and real-time cancer metastasis detection, a pH-responsive nanoplatform (NP) with dual-modality imaging capability was rationally designed. Herein, 1 H,1 H-undecafluorohexylamine (PFC), served as both an oxygen carrier 19 F magnetic resonance (MRI) probe, photosensitizer indocyanine green (ICG) were grafted onto peptide hexahistidine (H 6 ) to form H -PFC-ICG (HPI). Subsequently, heat shock protein 90 inhibitor, gambogic acid (GA), incorporated into hyaluronic (HA) modified HPI (HHPI), yielding ultimate HHPI@GA NPs. Upon self-assembly, NPs passively accumulated in tumor tissues, facilitating release HA-mediated cell uptake. Once phagocytosed by lysosomes, protonation triggered due low pH, resulting GA. With near-infrared laser irradiation, GA-mediated decreased HSP90 expression PFC-mediated increased ROS generation amplified PTT/PDT effect HHPI@GA, leading excellent vitro vivo anticancer efficacies. Additionally, fluorescence MRI dual-imaging capabilities enabled effective primary lung monitoring. This work offers novel approach for enhanced phototherapy, well precise diagnosis.

Language: Английский

Citations

6

The effects of tumor-derived supernatants (TDS) on cancer cell progression: A review and update on carcinogenesis and immunotherapy DOI Creative Commons

Sajjad Ahmadpour,

Mohammad Amin Habibi,

Farzaneh Sadat Ghazi

et al.

Cancer Treatment and Research Communications, Journal Year: 2024, Volume and Issue: 40, P. 100823 - 100823

Published: Jan. 1, 2024

Tumors can produce bioactive substances called tumor-derived supernatants (TDS) that modify the immune response in host body. This result immunosuppressive effects promote growth and spread of cancer. During tumorigenesis, exudation these disrupt function sentinels reinforce support for cancer cell growth. Tumor cells cytokines, factors, proteins, which contribute to progression tumor formation premetastatic niches. By understanding how influence system through secretion we gain new insights into diagnosis therapy.

Language: Английский

Citations

6

Identifying ITGB2 as a Potential Prognostic Biomarker in Ovarian Cancer DOI Creative Commons

Chanyuan Li,

Ting Deng,

Junya Cao

et al.

Diagnostics, Journal Year: 2023, Volume and Issue: 13(6), P. 1169 - 1169

Published: March 18, 2023

Epithelial ovarian cancer is by far the most lethal gynecological malignancy. The exploration of promising immunomarkers to predict prognosis in patients remains challenging. In our research, we carried out an integrated bioinformatic analysis genome expressions and their immune characteristics microenvironment with validation different experiments. We filtrated 332 differentially expressed genes 10 upregulated hub from Gene Expression Omnibus database. These were closely related tumorigenesis. Subsequently, survival infiltration demonstrated that upregulation five candidate genes, ITGB2, VEGFA, CLDN4, OCLN, SPP1, correlated unfavorable clinical outcome increased cell cancer. Of these ITGB2 tended be gene various infiltrations had a strong correlation significant M2 macrophages (r = 0.707, p 4.71 × 10−39), while it moderate CD4+/CD8+ T cells B cells. This characteristic explains why high expression was accompanied activation but did not reverse carcinogenesis. Additionally, confirmed over-expressed tissues mainly located cytoplasm, detected Western blotting immunohistochemical method. summary, may serve as prognostic immunomarker for patients.

Language: Английский

Citations

15

A novel thermoresponsive nano carrier matrix of hyaluronic acid, methotrexate and chitosan to target the cluster of differentiation 44 receptors in tumors DOI

Chandan Gupta,

Pinky Singh,

Shashikant Vaidya

et al.

International Journal of Biological Macromolecules, Journal Year: 2023, Volume and Issue: 243, P. 125238 - 125238

Published: June 7, 2023

Language: Английский

Citations

15

Cetuximab-based PROteolysis targeting chimera for effectual downregulation of NSCLC with varied EGFR mutations DOI Creative Commons
Richa Vartak, Bhavesh Deore, Carlos Sanhueza

et al.

International Journal of Biological Macromolecules, Journal Year: 2023, Volume and Issue: 252, P. 126413 - 126413

Published: Aug. 19, 2023

Language: Английский

Citations

13